{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"14.900","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"446,466,350","primaryexch":"香港交易所","ric":"2105.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BN95XV8","am":"178.93","iv":"","ew_strike":"","as":"14.890","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"14.880","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"4.440","shares_issued_date":"2025年9月17日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"呂向陽","underlying_ric":"2105.HK","hi52":"23.500","issuer_name":"來凱醫藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"12.760","mkt_cap":"6.64","f_aum_hkd":null,"ew_sub_per_to":"","ls":"14.880","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+2.060","aum":"","issued_shares_class_B":null,"vo":"12.65","secondary_listing_flag":false,"listing_date":"2023年6月29日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"來凱醫藥有限公司 - B","nm_s":"來凱醫藥－Ｂ","sym":"2105","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"來凱醫藥有限公司是一家主要從事癌症、肝臟疾病及肥胖症創新療法的發現、開發及商業化的投資控股公司。該公司尚處於研發階段。該公司的在研管線產品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一種三磷酸腺苷（ATP）競爭性AKT抑制劑。LAE001是雄性激素合成抑制劑，可同時抑制CYP17A1及CYP11B2。該公司主要在中國、美國、歐洲、韓國等市場開展業務。","op":"12.870","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>灣仔<br/>皇后大道東183號<br/>合和中心46樓","pc":"+16.07","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"12.820","isin":"KYG5340S1093","moneyness":""}},"qid":"1759074092582"}
